High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial

High concentrations of ivermectin demonstrated antiviral activity against SARS-CoV-2 in vitro. The aim of this study was to assess the safety and efficacy of high-dose ivermectin in reducing viral load in individuals with early SARS-CoV-2 infection. This was a randomised, double-blind, multicentre,...

Descripción completa

Detalles Bibliográficos
Autores principales: Buonfrate, Dora, Chesini, Fabio, Martini, Davide, Roncaglioni, Maria Carla, Ojeda Fernandez, Maria Luisa, Alvisi, Maria Francesca, De Simone, Irene, Rulli, Eliana, Nobili, Alessandro, Casalini, Giacomo, Antinori, Spinello, Gobbi, Marco, Campoli, Caterina, Deiana, Michela, Pomari, Elena, Lunardi, Gianluigi, Tessari, Roberto, Bisoffi, Zeno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734085/
https://www.ncbi.nlm.nih.gov/pubmed/34999239
http://dx.doi.org/10.1016/j.ijantimicag.2021.106516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734085/
https://www.ncbi.nlm.nih.gov/pubmed/34999239
http://dx.doi.org/10.1016/j.ijantimicag.2021.106516

Ejemplares similares